about
Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatinClinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reductionInChI in the wild: an assessment of InChIKey searching in GooglePediatric Statin Administration: Navigating a Frontier with Limited DataAdherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register studyDevelopment of In Vitro-In Vivo Correlation/Relationship Modeling Approaches for Immediate Release Formulations Using Compartmental Dynamic Dissolution Data from "Golem": A Novel Apparatus.A piece in the puzzle of personalized medicine.Quinine-induced renal failure as a result of rhabdomyolysis, haemolytic uraemic syndrome and disseminated intravascular coagulation.Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independenceSimvastatin protects bladder and renal functions following spinal cord injury in rats.Obesity, cholesterol metabolism, and breast cancer pathogenesisPreparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin.Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates.Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe.Pleiotropic effects of pitavastatinMolecular mechanisms underlying the effects of statins in the central nervous system.Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence.Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: a randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects.Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independenceEndothelial relaxation mechanisms and oxidative stress are restored by atorvastatin therapy in ovariectomized rats.Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasmaThe role of Multidrug Resistance-1 (MDR1) variants in response to atorvastatin among Jordanians.Treating statin-intolerant patientsCytochrome P450 Enzyme Metabolites in Lead Discovery and Development.Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice dailyEffect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulationDevelopment and optimization of a self-microemulsifying drug delivery system for atorvastatin calcium by using D-optimal mixture design.A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.Efficacy of alternate-day versus everyday dosing of atorvastatin.Torcetrapib/atorvastatin combination therapy.Effect of ATorvastatin On Chronic subdural Hematoma (ATOCH): a study protocol for a randomized controlled trial.Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.Clinical implications of pharmacogenomics of statin treatment.High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Atorvastatin and statins in the treatment of heart failure.Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatinAssessment of Potential Herb-Drug Interactions among Nigerian Adults with Type-2 DiabetesAtorvastatin Use Associated With Acute Pancreatitis: A Case-Control Study in Taiwan
P2860
Q24646870-E4FD546C-3853-4465-A9CE-E67D7C93E6F3Q26752950-EF2666E6-0E1B-43AB-AFA1-C03160782959Q27818912-EA6D9BF1-BC9C-4009-91CC-C544AD98AB15Q28068014-5480E401-E7B5-430C-8DA4-4D8FDBCA7D5AQ28535157-18A6178D-D828-4EB6-B723-2D80668E8D40Q30977297-13EFCB1B-D2D2-4393-AF6B-0633CCCC2FF1Q33348371-13230726-62D0-4162-B5F2-5A53045F155FQ33371596-B7B36CAF-73D0-468E-BBEF-C3A4561AFDFDQ33579568-DC11B820-79C2-4CC1-B23D-59F8E67F3A0DQ33864425-2024CD8C-6516-4524-AACA-60F5467D9837Q34204836-CF6FC28F-549A-4B3E-B65F-74E6C81D231CQ34562249-4727AE52-045F-4169-A9B8-422812612539Q34573885-0402DD49-0E42-4416-B609-A6C80867BC5CQ34579515-26AF217A-57C8-4881-80D2-3EAA3A457B61Q34633506-F5936C4C-DC8E-4402-8FDA-DF6114348D88Q34685463-B5458735-2EDA-48BA-A456-01508B52E34FQ34815981-707FD01C-0322-416B-B7ED-A03DF041E838Q35025924-B6A0258B-9D0D-4819-9D7A-0E465AB0EAE0Q35030507-09580A5F-364C-4DFF-AFC7-A97AECB9D9AFQ35053761-4D31086A-196C-412A-B1C7-7975EA3D77B8Q35071421-BFA76DCC-A957-4D06-AE98-A8E5162BBE1FQ35085937-5FE028E1-B6A4-409E-AD29-4D4EFC6D188DQ35110510-486402E4-789E-45C0-B5DB-3DA8E25781B7Q35194778-6E8DD440-E8F4-4D3B-9AEB-227570463CD2Q35219649-331910F4-0AB6-472F-BEB6-6D2E2BADC8A4Q35270890-90AC269E-1C55-481C-9BD0-C0995508C0D0Q35577240-8AE6453C-84A2-4199-BDA4-B3A48769AF2BQ35717232-82487F0D-79A6-4984-8315-4ADBF4233EC6Q35917726-F73C7B59-4A05-4F8C-A384-1162E7E801EDQ36021032-55F2C045-66C7-47F2-81CA-12A3BD910020Q36265996-38379822-BB0B-40F1-B990-EDF9C6E953E2Q36298592-41F5AC66-6563-410A-B83E-DC78223E95E1Q36390234-268B2E21-13C5-4C33-992D-4D8A167C69BDQ36426816-6E9E96B5-13DF-47AB-AB26-F37C24514953Q36832295-3B55A3C0-8DE2-4B4B-8A08-4A111E47A06DQ36986507-90EDEA91-3080-4F24-9DFC-8BE8BFC48A54Q37000767-0E293B1F-4187-4E40-9649-1D0D0AD11748Q37026626-8964CC07-55C4-4E39-A0A3-0D0AF448627FQ37162533-82C7CC55-8A67-4043-B426-DB763F672F5DQ37206046-3B99A9DE-5B2D-40AE-B18D-B56D9BDE3F74
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinical pharmacokinetics of atorvastatin.
@ast
Clinical pharmacokinetics of atorvastatin.
@en
type
label
Clinical pharmacokinetics of atorvastatin.
@ast
Clinical pharmacokinetics of atorvastatin.
@en
prefLabel
Clinical pharmacokinetics of atorvastatin.
@ast
Clinical pharmacokinetics of atorvastatin.
@en
P1476
Clinical pharmacokinetics of atorvastatin.
@en
P2093
Hans Lennernäs
P304
P356
10.2165/00003088-200342130-00005
P577
2003-01-01T00:00:00Z
P6179
1016134390